ImmuLogic
Executive Summary
Exec VP-Pharmaceutical Operations Robert Gerety, MD, succeeds Richard Bagley as president and CEO. Gerety joined ImmuLogic in September. He was formerly VP-pharmaceutical development at Biogen and previously was with Merck, NIH and FDA
Exec VP-Pharmaceutical Operations Robert Gerety, MD, succeeds Richard Bagley as president and CEO. Gerety joined ImmuLogic in September. He was formerly VP-pharmaceutical development at Biogen and previously was with Merck, NIH and FDA. |